Factors Influencing Long Term Persistence of Sinus Rhythm After a First Electrical Cardioversion for Atrial Fibrillation

It is conventionally thought that electrical cardioversion in patients with atrial fibrillation (AF) of longstanding duration or with a large lefi atrial diameter, only seldom results in long term success. Recurrence is common, although antiarrhythmic drugs often effectively decrease the number and duration of recurrent AF episodes. We analysed clinical, functional and pharmacological variables which could possibly infiuence the long term outcome after a first electrical cardioversion for AF in a retrospective study on 85 patients. Univariate and multivariate analysis was used to identify factors predicting maintenance of sinus rhythm at 100 days, and absence of recurrence during the entire follow-up. In univariate analysis, the only significant predictor for maintenance of sinus rhythm at 100 days was the duration of the preceding AF episode. Multivariate analysis with persistence of sinus rhythm at 100 days as endpoint confirmed this as a prognostic factor (p <0.03), but sotalol treatment also contributed to maintenance of sinus rhythm (p <0.05). When considering ihe entire observation period, class III antiarrhythmic drugs, i.e. sotalol ami amiodarone, were useful in preventing recurrence (p <0.01 and < 0.02). High age (above 75 years) was a predictor of recurrence. In conclusion, class III antiarrhythmic drugs, the duration of atrial fibrillation and high age were the most important determirumts of long term outcome, while echocardiographic parameters and the presence of heart disease played no role.     

Cardioversion of Atrial Fibrillation and Subsequent Maintenance of Sinus Rbythm

This article gives an overview of electrical cardioversion of AF and includes the discussion of newer strategies. DC external cardioversion is highly effective and carries a low risk of complications. Other approaches, like transesophageal cardioversion and high energy internal cardioversion, may improve the acute success rate but do not enhance long-term maintenance of sinus rhythm compared to external cardioversion. An atrial defibrillator may have important advantages which relate to the fact that the duration and possibly also the number of AF episodes become reduced. Supposedly, shortening the attacks of AF may exert an antiarrhythmic effect by limiting electrical, anatomical, and neurohumoral remodeling. So far. low energy biatrial defibrillation using an atrial defibrillator seems to be effective and safe (i.e., does not induce ventricular arrhythmias). However, discomfort limits its tolerability in clinical practice. Future improvement of leads and light sedation that is easy to administer may overcome this problem. In the second part of this overview, the probability of AF recurrence using a serial cardioversion approach is discussed. In middle-aged patients with a fair exercise tolerance and an arrhythmia duration < than 36 months this approach may be worthwhile. Young patients (age < 57 years) with an arrhythmia duration < 3 months and without hypertension may be cured from the arrhythmia with a single shock and without the institution of antiarrhythmic drugs. However, the serial electrical cardioversion approach is unlikely to succeed in elderly patients with a duration of AF exceeding 36 months and a poor exercise tolerance (NYHA Functional Class III or IV).     

A Decrease in Serum Aldosterone Level is Associated with Maintenance of Sinus Rhythm after Successful Cardioversion of Atrial Fibrillation

Background: The activation of the renin–angiotensin–aldosterone system has been implicated in the progression of atrial structural remodeling during atrial fibrillation (AF). However, consequences of the changes of aldosterone in AF have not been evaluated. Objectives: This study's aim was to evaluate changes of serum aldosterone concentration after successful cardioversion of persistent AF and to determine the prognostic value of these changes. Methods: The prospective, single center study included 45 consecutive patients with nonvalvular persistent AF and preserved left ventricular systolic function, referred for cardioversion. None of the patients were taking aldosterone antagonists. Blood samples for aldosterone measurement were collected twice: 24 hours before and 24 hours after cardioversion. Results: Forty‐three patients were successfully converted to sinus rhythm. On the 30th day following cardioversion, 24 patients maintained sinus rhythm (group A), 19 patients relapsed to AF (group B). Serum aldosterone concentration before cardioversion did not differ significantly between both groups (175.6 ± 112.82 pg/mL vs 125.8 ± 51.2 pg/mL; P = 0.25). However, in group A serum aldosterone level decreased significantly within 24 hours after cardioversion, from 175.6 ± 112.8 pg/mL to 101.4 ± 44.2 pg/mL (P = 0.0034). In group B, the aldosterone level before and after cardioversion did not differ significantly (125.8 ± 51.2 pg/mL vs 118.2 ± 59.6 pg/mL; P = 0.68). Logistic regression analysis revealed that a decrease in plasma aldosterone concentration after direct current cardioversion more than 13.2 pg/mL predicted sinus rhythm maintenance in a 30‐day follow‐up, with 87% sensitivity and 64% specificity. Conclusions: There is a positive correlation between the fall in aldosterone concentration 24 hours after cardioversion and maintenance of sinus rhythm during 30 days of observation. (PACE 2010; 561–565)     

Prediction of Maintenance of Sinus Rhythm after Cardioversion of Atrial Fibrillation by Analysis of Serial Signal-Averaged P Waves

After cardioversion from atrial fibrillation (AF) many patients develop early recurrence of the arrhythmia. While these patients may be appropriate for immediate prophylaxis against AF recurrence their identification at the time of cardioversion is not possible. Since the signal-averaged P wave (SAPW) is abnormal in individuals with atrial arrhythmia, we assessed its utility for predicting early AF recurrence after cardioversion. Seventy-five cardioversions in 31 patients were evaluated. The mean age was 59 (range 28–79) years; 26 were male. Fifty-eight cardioversions were internal using low energy biphasic DC shocks delivered via electrodes placed in the right atrial appendage and coronary sinus. P wave specific signal averaging was performed at 3 and 24 hours after each cardioversion to estimate filtered P wave duration and energy from 20, 40, and 60 to 150 Hz. Follow-up was by regular clinic visits and transtelephonic ECG monitoring. Early recurrence of AF (prospectively defined as sinus rhythm duration < 1 week) occurred after 30 cardioversions. No differences were found in any P wave variable measured at 3 hours between these cardioversions and those that resulted in a longer duration of sinus rhythm. Paired 3- and 24-hour signal-averaged data were available in 47 cardioversions. There were significant falls in P wave energy from 3 to 24 hours after 31 cardioversions that resulted in sinus rhythm for > 1 week, (P40: 3 hours 11.2 [±1.5] μV²· s, 24 hours 8.6 [±1.2] μV²· s, P < 0.001), but not following the 16 after which AF returned within 1 week (P40: 3 hours 9.0 [±1.2] μV²· s, 24 hours 8.5 [±1.2] μV²· s, P = NS). A fall in P40 of > 25% had a positive predictive accuracy for maintenance of sinus rhythm of 87%; negative predictive accuracy was only 37%. Similar falls in P wave energy occurred after cardioversions that resulted in longer term (> 4 weeks) sinus rhythm, but not in those that did not. However, the predictive accuracy of a fall in P40 was less (positive predictive accuracy 38%, negative predictive accuracy 62%). Patients with relapsing permanent AF who remain in sinus rhythm for at least 1 week after cardioversion show a fall in P wave energy within the first 24 hours. However, in these patients the technique does not predict recurrent AF within 1 week nor sinus rhythm > 4 weeks. These observations suggest persistent disordered atrial activation as a mechanism for early recurrence of AF after cardioversion.     

Intravenous Propafenone Versus Intravenous Amiodarone in the Management of Atrial Fibrillation of Recent Onset: A Placebo-Controlled Study

The efficacy and safety of intravenous propafenone, amiodarone, or placebo were compared in the treatment of atrial fibrillation (AF) of recent onset (duration ≤ 48 hours). Methods: 143 patients (77 men, mean age 63 ± 12 years) were studied, of whom 46 received propafenone (2 mg/kg over 15 minutes followed by 10 mg/kg over the next 24 hours), 48 received amiodarone (300 mg intravenously over 1 hour, followed by 20 mg/kg over the next 24 hours, plus 1,800 mg/day orally, in 3 divided doses), and 49 received placebo (the equivalent amount of saline IV over 24 hours). Digoxin was administered to all patients who had not previously received it. Results: Conversion to normal sinus rhythm occurred in 36 of 46 patients (78.2%) receiving propafenone, in 40 of 48 patients (83.3%) receiving amiodarone, and in 27 of the 49 (55.10%) controls (P < 0.02, drug vs placebo, between drugs NS). The mean time to conversion was 2 ± 3 hours for propafenone, 7 ± 5 hours for amiodarone, and 13 ± 9 for placebo (P < 0.05). Patients who converted had smaller atria than those who did not (diameter: 42.7 ± 5 vs 47.2 ± 7 mm, P < 0.001 for all). Treatment was discontinued in one patient in the amiodarone group because of an allergic reaction and in two patients in the propafenone group because of excessive QRS widening. No side effects were observed in the placebo group. Conclusions: Both drugs tested intravenously were equally effective and safe for the rapid conversion of recent-onset atrial fibrillation to sinus rhythm. However, propafenone offered the advantage of more rapid conversion than amiodarone.     

Improved Clinical Efficacy of External Cardioversion by Fluoroscopic Electrode Positioning and Comparison to Internal Cardioversion in Patients with Atrial Fibrillation

Background: Despite using different electrode positions, “conventional” external DC cardioversion in patients with atrial fibrillation is ineffective in 6%–50% of cases. An alternative when DC cardioversion is not successful is low energy internal cardioversion, which is performed at increased risk. We tested the hypothesis that optimization of electrode pad position under fluoroscopy to encompass as much atrial muscle as possible might improve the success rate of external cardioversion and thus minimize the need for internal cardioversion. Methods: Fifteen (9 males, 6 females) patients (age: 54 ± 15 years, weight: 124 ± 35 kg) with chronic atrial fibrillation (> 8 weeks) who had undergone unsuccessful conventional external cardioversion entered the study. Repeat conventional external cardioversion with electrodes in standard (right anterior and left posterior) positions was followed by “optimized” external cardioversion by positioning electrodes under fluoroscopy (using metallic markers). In case of failure, internal cardioversion was performed. Results: All 15 patients had undergone unsuccessful conventional external cardioversion with 360-J shocks. Eight patients (group A) reverted to sinus rhythm with one or two 360-J shocks using fluoroscopy-guided pad placement (53%). Six of the remaining 7 (86%) patients (group B) had successful internal cardioversion with biphasic shocks (12 ± 3 J). The body weight and body mass index were statistically lower in group A vs group B (106 ± 27 vs 145 ± 33 kg, p = 0.03 and 35 ± 8 vs 45 ± 8 kg/m², P = 0.48, respectively). There was no statistically significant in age, height, body surface area, duration of atrial fibrillation, amiodarone therapy, ejection fraction, or underlying heart disease. Conclusion: Unsuccessful external DC cardioversion, in some patients, is in part due to suboptimal conventional positioning of electrode pads that can be improved under fluoroscopic guidance by achieving the best possible vector encompassing the right and left atria. The optimized external cardioversion technique may minimize the need for internal cardioversion, which remains an effective approach when external cardioversion fails.     

Atrial Ejection Force in Patients with Atrial Fibrillation: Comparison Between DC Shock and Pharmacological Cardioversion

It is well known that the restoration of sinus rhythm is not always associated with the return of effective atrial contraction. Atrial ejection force (AEF) is a noninvasive Doppler derived parameter that measures the strength of the atrial contraction. The aim of the present study was to use pulsed-Doppler echocardiography to determine if different modalities of cardioversion influence the delay in the return of effective atrial contraction after cardioversion. DC shock and pharmacological therapy were compared. Sixty-eight patients were randomly cardioverted, either using DC shock or i.v. procainamide. The patients who were restored to a sinus rhythm had a complete Doppler echocardiographic examination within 1 hour after the restoration, after 24 hours, after 1 month, and after 3 months. AEF was measured and compared in the two groups of patients and within the same group. AEF was greater immediately and at 24 hours after cardioversion in patients who underwent pharmacological therapy compared to patients treated with DC shock (peak A wave, 60 ± 9 vs 31 ± 8 msec, P < 0.001; AEF 11.3 ± 3 vs 5 ± 2.9 dynes, P < 0.001). In both groups, AEF increases over time. In conclusion, AEF is a noninvasive parameter that can be easily measured after cardioversion and can give accurate information about the recovery of left atrial mechanical function. This finding may have important implications for guiding the anticoagulant therapy after cardioversion.     

Ventricular Pauses during Atrial Fibrillation Predict Relapse after Electrical Cardioversion: A Prospective Study

Aims: To investigate the use of ambulatory electrocardiogram (ECG) monitoring in atrial fibrillation (AF) to predict recurrence after electrical cardioversion (ECV). Methods: RR interval variables were obtained from 24 hours ECGs recorded before ECV in 119 patients (85 men, age 66 ± 10 years) with persistent AF. Patients were followed for 1 month. Results: Of the 119 patients, 16 (13%) failed ECV and 65 (55%) were in AF at 1 week and 81 (68%) at 1 month after ECV. The maximum RR interval (RR‐max) and the minimum RR interval (RR‐min) during AF were found to be reproducible. The RR‐max was longer in those who had AF 1 week (2.55 ± 0.49 vs 2.01 ± 0.52 seconds, P = 0.005) and 1 month (2.56 ± 0.50 vs 1.89 ± 0.43 ms; P < 0.001) after ECV than in those who maintained sinus rhythm. Those in AF at 1 month included more patients with RR‐max ≥ 2.8 seconds (31% vs 11% P = 0.021). The average heart rate was lower in patients with RR‐max ≥ 2.8 seconds, but the average rate was not predictive of AF recurrence. Conclusion: Ventricular pauses during AF predict relapse after ECV. (PACE 2010; 934–938)     

静脉注射胺碘酮与心律平转复阵发心房颤动的疗效比较

目的对比研究胺碘酮与心律平转复阵发心房颤动的疗效。方法阵发心房颤动(此次病程≤48h)患者58例随机分为两组胺碘酮组30例,给予胺碘酮负荷量150mg静注后,继以0·6~1·0mg/min维持点滴,依心室率情况调整胺碘酮剂量。心律平组28例,静脉给予心律平1·4~2·0mg/kg,5min内注射,继以0·28mg/min维持静点,无效者改用胺碘酮治疗。结果胺碘酮组转复成功率为86·7%(26/30),心律平组转复成功率57·1%(16/28),且心律平组转复心律失败的部分病例使用胺碘酮仍有效;胺碘酮组平均复律时间(101±95)min(6~508min),心律平组(172±148)min(11~608min)。结论胺碘酮在转复阵发心房颤动比心律平更加快速、安全、有效。     

Efficacy of Biphasic Shock for Transthoracic Cardioversion of Persistent Atrial Fibrillation:

Although electrical cardioversion of atrial fibrillation (AF) is frequently performed, initial energy requirements for cardioversion of persistent AF is still a matter of debate. The aim of the study was to determine the efficacy of biphasic shocks for transthoracic cardioversion of persistent AF and to predict adequate initial energy. A prospective study enrolled 94 consecutive patients with persistent AF, who were referred for elective cardioversion with a biphasic waveform. The paddles were placed in the anterolateral position. A step-up protocol was used to estimate the cardioversion threshold. The initial shock energy was 50 J, with subsequent increments to 100, 200, and 300 J in the event of cardioversion failure. The mean age of the study group was of about 65 years (6 ± 11 years) and a median duration of AF was 65 days (3–324). Sixty-two out of 94 patients were men, 55% of the study population was classified as having well-controlled hypertension. The overall success rate of cardioversion was 89%, with a mean 2.2 ± 1.4 shocks, and effective J 217.8 ± 113 delivered during repeated cardioversions. The success rate of low energy shocks: 50 and 50 +100 J was 51%. By logistic regression analysis the only independent predictor of success at low energy shock was shorter duration of AF (r =−0.51; P = 0.02). Patients with shorter duration of AF have a higher probability for successful cardioversion with low energy. In patients with longer AF duration, a 200 J shock should be considered for cardioversion as the initial energy. (PACE 2004; 27[Pt. I]:764–768)     

口服普罗帕酮与胺碘酮联合电复律转复持续性房颤的随机对照试验

目的比较普罗帕酮与胺碘酮联合电复律转复持续性心房颤动及维持窦性心律的疗效与安全性。方法将60例基础疾病治疗良好的持续性房颤患者随机分为两组,每组各30例。普罗帕酮组:普罗帕酮600mg顿服后观察6h,未转复者予电复律,并以最低有效量口服维持窦律;胺碘酮组:胺碘酮600mg分3次口服,连服7天,未转复者电复律,以最低有效量维持窦律。结果单纯药物复律,普罗帕酮组4例,胺电酮组3例,联合电复律两组分别转复25例和22例,两组早期有效率分别为90.0%和80.0%,晚期有效率分别为73.3%和70.0%,两组比较差异无统计学意义。住院时间普罗帕酮组短于胺碘酮组(P<0.001)。普罗帕酮组1例服药后出现一过性低血压,放弃复律,经对症治疗后好转;胺碘酮组4例服药后恶心、呕吐,未能坚持负荷量连服7天;但两组副反应发生率差异无统计学意义。结论普罗帕酮与胺碘酮联合电复律治疗持续心房颤动安全而有效,但普罗帕酮起效快,可相对减少患者的住院时间。     

Safety of High Energy Internal Cardioversion for Atrial Fibrillation

High energy internal cardioversion has been proposed as an alternative method to cardiovert drug refractory or external cardioversion refractory atrial fibrillation. However, the safety of this technique has not been clearly evaluated. We reviewed findings in 53 patients who underwent 55 sessions of high energy internal cardioversion (2 patients underwent 2 sessions] for termination of longstanding atrial fibrillation. Shocks energy varied from 70–270 J. Three patients had 3 shocks during the same session, 5 had 2, and 47 only 1. Success rate was 89% (success was defined as immediate conversion to normal sinus rhythm).
Low cardiac output occurred in two patients, and resulted in the death of one of these individuals, a patient with significant hypertrophic cardiomyopathy and heart failure. The other patient recovered completely. In 11% of the cases, shock induced transient atrioventricular block, necessitating ventricular pacing until sinus rhythm was restored. In three patients, a moderate but asymptomatic and uncomplicated pericardial effusion was diagnosed on echocardiogram. Finally, four patients had side effects related to venous puncture, which resolved spontaneously. These results suggest that high energy internal cardioversion is effective for conversion of atrial fibrillation. However, the technique may not be optimal in patients with advanced hypertrophic cardiomyopathy and in such cases the technique should be used carefully and only in the case of failure of external cardioversion; no more than two shocks should be delivered during the same procedure. Temporary ventricular pacing should be provided in all patients and an echocardiogram should be performed before patients are being discharged.     

Regular Ventricular Rhythms Before Conversion of Recent Onset Atrial Fibrillation to Sinus Rhythm

The incidence of fast atrial tachycardias with regular ventricular rhythm was assessed in a population of 243 patients with recent onset (< 72 hours) atrial fibrillation (AF), without heart failure, randomly treated with single loading oral dose of propafenone (600 mg), flecainide (300 mg), digoxin (1 mg), or placebo for acute conversion to sinus rhythm (SR). Fast atrial arrhythmias developed in 14 (6%) patients: 6/92 treated with propafenone, 3/34 treated with flecainide, 1/25 treated with digoxin, and 4/ 92 who received placebo (P = NS). Heart rate > 175 beats/min with 1:1 AV conduction ensued in 4 cases: 2 treated with flecainide and 2 treated with placebo; in the other cases 2:1 AV conduction was observed. Widening of QRS during regular tachycardia was observed in 4 patients; 3 who received propafenone and 1 who received flecainide. Conversion to SR within 4 hours was achieved in 55/92 (60%) patients treated with propafenone, 20/34 (59%) patients treated with flecainide, 7/25 (28%) patients treated with digoxin, and 19/92 (20%) treated with placebo (P < 0.001 propafenone vs placebo and flecainide vs placebo; P < 0.05 propafenone vs digoxin and flecainide vs digoxin). Periods of regular tachycardia are expected in recent onset AF and may not necessarily represent a proarrhythmic effect of Class 1C drugs, rather than mark the transition from AF to SR. Class 1C agents are probably responsible for widening of the QRS complex seen during these tachycardias. Propafenone and flecainide appear equally effective in converting recent onset AF.     

Internal Cardioversion of Chronic Atrial Fibrillation in Patients

Transvenous internal cardioversion of chronic AF using a right atrium (RA) coronary sinus (CS) vector requires more energy than cardioversion of paroxysmal AF. Chronic AF is not terminated in 25% of patients using biphasic shocks up to 10 J. We therefore evaluated efficacy, safety, and tolerability of internal cardioversion using a "unipolar' configuration (RA to skin patch) and biphasic shocks in patients with long-lasting AF and different heart disease. In each patient, biphasic R have synchronous shocks were delivered between a large defibrillating surface area electrode in the RA and a skin patch in the left prepectoral position. Defibrillation protocol started with a test shock of 0.4 J. Shocks were repeated and increased until termination of AF or a maximum of 34 J. Sedation was used when the patient described the shock as painful. This study included 11 patients with a mean age of 67 ± 8 years (range 56–83). AF duration was ± 1 month in all patients with a mean duration of 11 ± 11 months (range 2–36). Underlying heart disease was present in all patients and the mean left atrial dimension was 43 ± 9 mm (range 26–57). AF was terminated in 10 of 11 patients (91 %) with a mean delivered energy of the successful shocks of 18.7 ± 8.7 J (median energy 16.9 J; range 7.3–32.5) and a mean leading edge voltage of 564 ± 129 V. The mean shock impedance at the defibrillation threshold was 71 ± 13 Ω, (range 59–103). A total of 131 shocks were delivered without any complication and proarrhythmia episodes. We conclude that low energy "unipolar" internal cardioversion is a simple, safe, and effective technique for termination of chronic AF in patients with heart disease. The procedure is often tolerated under light sedation.     

Quadruple Pads Approach for External Cardioversion of Atrial Fibrillation

MARROUCHE, N.F., et al. : Quadruple Pads Approach for External Cardioversion of Atrial Fibrillation. This study examined the alternative of transthoracic quadruple pads shock delivery of two simultaneous 360-J shocks to convert refractory AF in patients failing standard external cardioversion. Forty-six patients (  mean age 58 ± 11 years, 23 men  ) with chronic AF (  duration 14 ± 17 months, range 1–60 months  ) were included. The left atrial diameter was  47 ± 7 mm  . The left ventricular ejection fraction was  59 ± 11%  . Antiarrhythmic drugs had failed to convert 44 (96%) of these patients. All patients underwent conventional external transthoracic cardioversion with pads applied in the antero-apical position using energy settings of 200 and 360 J, consecutively. In all patients who failed conventional cardioversion, quadruple pads were applied. Quadruple pads consisted of four pads, two in the antero-posterior position and two in a second apex-posterior position. Standard cardioversion to sinus rhythm was successful in 19 (41%) patients after use of a single 200-J shock and an additional 8 (17%) after a single 360-J shock. The total success rate was 58% after conventional cardioversion. The quadruple pads were successful in 14 (74%) of the remaining 19 patients. Four of the five patients who failed the quadruple pads approach subsequently also failed internal cardioversion. Thus, the cardioversion success rate was increased from 48% using the conventional approach to 89% using the quadruple pads approach. Quadruple pads external cardioversion is highly effective in converting chronic AF refractory to standard shock protocols to sinus rhythm. Moreover, the failure of the quadruple pads approach seems to predict poor response to internal cardioversion.     

Multiple Shocks Affect Thoracic Electrical Impedance During External Cardioversion of Atrial Fibrillation

Background: Thoracic impedance (TI) influences the success of external cardioversion (ECV) or defibrillation because current intensity traversing the heart is inversely related to TI. Experimental data suggest that TI decreases after multiple shocks. We undertook a clinical study to determine changes of TI values in patients with atrial fibrillation or flutter requiring ECV. Methods: We enrolled 222 consecutive patients (age 73 ± 11 years; males 67%; body weight 75 ± 13 kg) who underwent ECV between January 2004 and February 2007. Biphasic shocks were delivered through adhesive pads placed in the anteroposterior position. The initial energy was set at 1 J/kg, with progressive increases up to a maximum of 180 J in case of failure. In the last 39 elective patients, plasma concentration of interleukin‐6 (IL‐6) and tumor necrosis factor (TNF)‐α were determined before and 6 hours after ECV. Results: Sinus rhythm was restored in 202 patients (91.0%). Of these, 155 (69.8%) required more than one shock (on average, 2.5 ± 1.5 shocks/patient). Final values of energy and peak current intensity were 136 ± 47 J and 50 ± 14 A, respectively. TI decreased significantly by 6.2% from baseline after ≥2 shocks (P < 0.001). The absolute reduction was correlated with baseline TI, number of delivered shocks, and hemoglobin oxygen saturation. IL‐6 and TNF‐α increased with ECV (P < 0.001 and P = 0.014, respectively). Conclusions: TI decreases significantly after multiple shocks, possibly by activation of acute inflammation.     

Randomized, Crossover, Controlled Comparison of Oral Loading Versus Intravenous Infusion of Propafenone in Recent-Onset Atrial Fibrillation

A population of 123 patients witb recent-onset (< 72 hours) atrial fibrillation (AF) without heart failure was randomly treated witb propafenone (PFN) intravenously (IV) (2 mg/kg bolus followed by 0.0078 mg/kg/min infusion) or in a single oral dose (os) (600 mg), or with placebo (PLA) (phase 1). If AF persisted 8 hours later, patients on active drugs received the alternative formulation (crossover), and patients receiving PLA remained on PLA (phase 2). A 24-hour Holter monitoring was performed and conversion to sinus rhythm (SR) at 1,4, and 8 hours of each phase was used as the criterion of efficacy. Conversion to SR occurred within 1 hour in 48% of patients witb IV-PFN, 15 % witb os-PFN, and in 17% with PLA (both P<0.05 vs IV-PFN). Oral PFN was superior to PLA at 4 hours (71 % vs 33%, P = 0.001) and 8 hours (78% vs 48%, P < 0.01), and 1 at 8 hours also superior to IV-PFN (53%, P < 0.03). The mean conversion time within 4 hours was shorter with IV-PFN (25 ± 15') than with os-PFN (167 ± 166, P < 0.001) or with PLA (156 ±107', P < 0.001). The rates of conversion to SR with IV-PFN after os-PFN failure were comparable to PLA at any observation time, whereas nonresponders to IV-PFN who received os-PFN had significantly higher conversion rates than with placebo at both 4 hours (65% vs 19%) and 8 hours (76% vs 24%; both P < 0.045). Neither serious adverse effects nor episodes of regular tachycardia with 1:1 AV conduction were noted. PFN administered intravenously or in a single oral loading dose was safe and efficacious in converting recent-onset AF to SR. The rates of conversion were different with different routes of administration: IV-PFN was superior to os-PFN over a short observation period, while the overall efficacy of os-PFN was superior at 8 hours.     

Guideline-based Management of Patients With Atrial Fibrillation

Atrial fibrillation (AF) has become a significant public health concern. An epidemiologic study conducted in 2010 estimated there are over 33.5 million people worldwide diagnosed with AF with that number predicted to rise by 5% annually. In the United States, AF is the primary diagnosis in over 500,000 hospital admissions annually. Guideline-based knowledge of treatment options is imperative in decreasing stroke risk, prevention of worsening heart function, and maintaining quality of life. It is also important for nurse practitioners to have this knowledge to make educated treatment recommendations to keep our patients safe and to help them to set realistic expectations.     

Low Energy Internal Atrial Cardioversion in Atrial Fibrillation Lasting More Than a Year

The aim of this study was to evaluate the efficacy of low energy internal atrial cardioversion in restoring sinus rhythm (SR) in patients with chronic atrial fibrillation (AF) persisting > 1 year. Fifteen patients with chronic AF lasting > 1 year (from 13–48 months, mean 24 ± 13 months) were studied. R wave synchronized 3/3 ms biphasic shocks were delivered between right atrial and coronary sinus (left pulmonary artery in five patients) electrodes. Sedatives or anesthetics were administered only at the patient's request. Results: Stable SR was restored in 14 (93%)of 15 patients after shocks with a mean leading edge voltage of 377 ± 77 V (range 260–500) and a mean delivered energy of 7.3 ± 3.4 J (range 2.6–12.9). The procedure was performed without anesthesia in 6 (40%) patients. All successfully cardioverted patients were treated with flecainide, sotalol, or amiodarone. During a follow up of 7.7 ± 7.9 months (range 1–24) AF recurred in five (36%) patients. Three of five AF recurrences occurred within 3 days after conversion to SR. Conclusion: Internal low energy atrial cardioversion is highly effective in restoring SR even in patients with AF lasting > 1 year. The long-term results from the standpoint of freedom from AF recurrences, are satisfactory, although additional antiarrhythmic treatment is required, particularly in the first days after conversion.